Retrospective Study
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastrointest Oncol. May 15, 2014; 6(5): 139-144
Published online May 15, 2014. doi: 10.4251/wjgo.v6.i5.139
Table 1 Influence of patient characteristics on maximum standardized uptake value and survival
FactorMean SUVmax (95%CI)Median survival in days (95%CI)
Sex
Male (n = 191)11.4 (10.5, 12.3)566 (491, 641)
Female (n = 80)12.1 (10.2, 14.0)884 (403, 1364)
P = 0.950P = 0.05
Age in years
Age ≤ 65 (n = 136)11.5 (10.5, 12.5)575 (456, 694)
Age > 65 (n = 135)11.7 (10.4, 13.1)586 (418, 754)
P = 0.770P = 0.25
Histology
Adenocarcinoma (n = 197)11.3 (10.2, 12.4)570 (483, 657)
Squamous carcinoma (n = 74)12.4 (11.3, 13.6)629 (445, 813)
P = 0.008P = 0.75
Tumor location
Upper esophagus (n = 13)15.6 (11.4, 19.8)973 (142,1804)
Mid esophagus (n = 50)12.8 (11.0, 14.6)425 (252, 598)
Lower esophagus (n = 136)10.8 (9.6, 12.0)586 (464, 708)
Junctional (n = 72)11.6 (10.0, 13.1)684 (430, 938)
P = 0.010P = 0.14
Table 2 Influence of cancer stage on maximum standardized uptake value and survival
FactorMean SUVmax (95%CI)Median survival in days (95%CI)
T stage
T0 or T1 (n = 15)3.1 (1.5, 4.7)Not reached
T2 (n = 49)8.7 (7.0, 10.4)1225 (742, 1708)
T3 (n = 183)12.7 (11.7, 13.7)495 (413, 577)
T4 (n = 24)14.1 (11.6, 16.7)390 (186, 594)
P < 0.001P < 0.001
N stage
N0 (n = 107)9.1 (8.1, 10.2)1094 (835, 1352)
N1 (n = 89)12.9 (11.4, 14.5)466 (371, 561)
N2 (n = 61)13.4 (11.6, 15.1)477 (307, 646)
N3 (n = 14)14.4 (8.8, 19.9)530 (350, 710)
P < 0.001P < 0.001
UICC stage
Stage 0 or 1 (n = 45)5.6 (4.2, 7.0)2092 (1060, 3124)
Stage 2 (n = 50)12.1 (10.6, 13.6)780 (195,1365)
Stage 3 (n = 99)11.9 (10.7, 13.2)594 (473, 715)
Stage 4 (n = 77)14.4 (12.6, 16.1)349 (280, 418)
P < 0.001P < 0.001
Table 3 Influence of treatment intent and modality on maximum standardized uptake value and survival
FactorMean SUVmax (95%CI)Median survival in days (95%CI)
Treatment intention
Curative (n = 182)10.6 (9.7, 11.5)984 (699, 1269)
Palliative (n = 89)13.6 (11.9, 15.2)370 (332, 408)
P = 0.001P < 0.001
Treatment type
Endoscopic resection (n = 5)1.3 (-1.0, 3.6)Not reached
Surgical resection (n = 95)10.7 (9.5, 11.9)1285 (962, 1608)
Chemoradiotherapy (n = 63)11.6 (10.0, 13.1)700 (411, 988)
Palliative (n = 89)13.8 (12.1, 15.5)370 (349, 390)
Exploratory surgery (n = 19)8.8 (6.6, 11.0)340 (280, 400)
P < 0.001P < 0.001
Table 4 Summary of literature reporting on prognostic value of maximum standardized uptake value in patients with esophageal carcinoma
Ref.Patients (n)Adeno-carcinoma (%)Treatment intention of studied groupMedian (or mean) SUVmaxSUVmax significant on univariate analysisSUVmax significant on multivariate analysisOther significant associations on multivariate analysis
Fukunaga et al[4], 199848Not statedCurative7YesNot assessedNot assessed
Choi et al[5], 2004690%Curative6.3/13.7 (thresholds)YesNoUICC stage
Hong et al[6], 20054787%CurativeNot statedNoNoNumber of abnormalities on PET-CT
Stahl et al[7], 200540100%Curative10.5NoNot assessed
van Westreenen et al[8], 20054070%Curative and palliative6.7YesNoTreatment
Cerfolio et al[9], 20068953%Curative6.6YesYesUICC stage
Choi et al[10], 2006510%CurativeNot statedYesNoUICC stage, N1 status (on PET-CT), immunohistochemical markers
Westerterp et al[11], 200826100%Curative0.26YesNot assessed
Omloo et al[12], 200812585%Curative0.27YesNoUICC stage
Cheze-Le Rest et al[13], 20084777%Curative9YesYesTreatment, number of abnormalities on PET-CT
Chatterton et al[14], 200812919%Curative and palliative8.2NoNot assessedNot assessed
Makino et al[15], 200838100%Curative11.1YesNoN1 status (on PET-CT)
Javeri et al[16], 2009161100%Curative10.1NoNo
Kato et al[17], 20091840%Curative4.5YesYesN1 status
Rizk et al[18], 2009189100%Curative4.5 (preset threshold)YesNot assessedNot assessed
Sepesi et al[19], 20097283%Curative6.2YesYes
Shenfine et al[20], 200945100%Curative5.7YesNoUICC stage
Hyun et al[21], 20101513%Curative and palliative17.2YesNoUICC stage, metabolic tumor volume
Brown et al[22], 201210380%Curative6.4 (early)/8.8 (later scans)YesNoN1 status, age
Gillies et al[23], 2012121100%Curative8.5YesNoN1 status (on PET-CT)
Chan et al[24], 201318575%Curative and palliative8.9YesNoN1 status, tumor volume on EUS